全球首创的CLDN18.2 CAR-T细胞药物被美国FDA授予“孤儿药”称号

CARsgen Therapeutics Receives IND Clearance from the NMPA for CT041 CLDN18.2-CAR-T Cells

CARsgen Announces the Publication of a Novel CAR-T Technology that Improves the Efficacy of CAR-T cells Against Solid Tumors without Requiring Preconditioned Lymphodepletion

CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells (CT053) for the Treatment of Multiple Myeloma

科济生物任命范勇博士担任全球注册事务高级副总裁

科济生物在2019年ASH年会展示CT053治疗复发/难治多发性骨髓瘤的临床研究结果

CARsgen Therapeutics Receives IND Clearance from the NMPA for AB011 Humanized Claudin18.2 Monoclonal Antibody

科济生物“重组人源化抗Claudin 18.2单克隆抗体注射液”获NMPA临床试验许可

科济生物CT053细胞治疗产品被FDA授予再生医学先进疗法资格

科济生物CT053细胞治疗产品被纳入欧洲药品管理局优先药物计划